{
    "title": "FDA bars critic from review panel of Biogen's controversial Alzheimer's drug",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8906615/FDA-bars-critic-review-panel-Biogens-controversial-Alzheimers-drug.html",
    "date": "2020-11-02",
    "keywords": [
        "aducanumab",
        "drug",
        "biogen",
        "fda",
        "beasley",
        "knopman",
        "approval",
        "trial",
        "benefit",
        "food",
        "administration",
        "conflict",
        "interest",
        "member",
        "committee",
        "mayo",
        "neurologist",
        "dr",
        "monday",
        "meeting",
        "role",
        "agency",
        "advice",
        "involvement",
        "critic",
        "paper",
        "sunday",
        "journal",
        "efficacy",
        "treatment",
        "dysfunction",
        "march",
        "request",
        "comment",
        "cause",
        "mindwasting",
        "disease",
        "field",
        "nothing",
        "failure",
        "number",
        "age",
        "association",
        "antibody",
        "brain",
        "cognitive",
        "decline",
        "subset",
        "dose",
        "year",
        "look",
        "biotech",
        "company",
        "course",
        "reporting",
        "deena",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}